Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
نویسندگان
چکیده
BACKGROUND The treatment of chronic hepatitis C virus infection has been revolutionized by the advent of direct-acting antiviral agents. However, evidence of its effects on patients with acute hepatitis C (AHC) virus infection is limited. CASE SUMMARY We report the case of a patient with decompensated cirrhosis induced by autoimmune liver disease, whose condition rapidly deteriorated following AHC virus infection. The patient received sofosbuvir and ribavirin combination treatment for 12 weeks. Serum hepatitis C virus RNA remained undetectable 36 weeks after discontinuing sofosbuvir and ribavirin. CONCLUSION Our findings support the use of sofosbuvir and ribavirin as a treatment in AHC patients with decompensated cirrhosis.
منابع مشابه
Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
OBJECTIVE To compare sustained viral response to sofosbuvir/ribavirin ±interferon therapy in patients of hepatitis C with and without liver cirrhosis. METHODS This observational study of chronic hepatitis C patients was carried out at Doctors Hospital and Medical Center (DH&MC). After diagnostic workup, Sofosbuvir/ribavirin for 24 weeks or sofosbuvir/ribavirin/pegylated interferon for 12 week...
متن کاملSofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report
BACKGROUND Recurrent hepatitis C virus infection after liver transplantation is associated with reduced graft and patient survival. Re-transplantation for graft failure due to recurrent hepatitis C is controversial and not performed in all centers. CASE PRESENTATION We describe a 54-year-old patient with hepatitis C virus genotype 1b infection and a null response to pegylated interferon-α and...
متن کاملRole of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-related mortality throughout the world. Among the six HCV genotypes, genotype 1 was significantly more aggressive when utilizing the combination of pegylated interferon and ribavirin, as genotype 1-infected patients had the lowest likelihood of achieving cure (40%-50%) and required twice as long duration of ...
متن کاملSimeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
Hyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin level have also been reported in patients with decompensated cirrhosis. We describe a 51-year-old female patient with HbS beta 0-thalassemia a...
متن کاملThe effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
BACKGROUND There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options. METHODS A retrospective multi-country cohort of patients with chronic hepatitis C who received d...
متن کامل